Rasna Therapeutics Inc
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, develops therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma in the United States. It is developing RASP-201, an orally dosed selective reversible inhibitor of lysine specific demethylase (LSD1), which is a pathway that blocks differentiation and confers a poor prognosis to A… Read more
Rasna Therapeutics Inc (RASP) - Total Liabilities
Latest total liabilities as of March 2024: $2.23 Million USD
Based on the latest financial reports, Rasna Therapeutics Inc (RASP) has total liabilities worth $2.23 Million USD as of March 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Rasna Therapeutics Inc - Total Liabilities Trend (2013–2023)
This chart illustrates how Rasna Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Rasna Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Rasna Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TRACTOR SUPPLY (TR4.SG)
STU:TR4
|
Germany | €7.48 Billion |
|
KOMATSU
MU:KOM1
|
Germany | €2.44 Trillion |
|
AdvanceTC Limited
PINK:ATCLF
|
USA | $14.91 Million |
|
Cavalry Capital Corp.
V:CVY-P
|
Canada | CA$28.45K |
|
Rekah Pharmaceutical Industry Ltd
TA:REKA
|
Israel | ILA264.28 Million |
Liability Composition Analysis (2013–2023)
This chart breaks down Rasna Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 45.88 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rasna Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rasna Therapeutics Inc (2013–2023)
The table below shows the annual total liabilities of Rasna Therapeutics Inc from 2013 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-09-30 | $2.05 Million | +15.65% |
| 2022-09-30 | $1.77 Million | -34.48% |
| 2021-09-30 | $2.71 Million | -0.01% |
| 2020-09-30 | $2.71 Million | +12.42% |
| 2019-09-30 | $2.41 Million | +13.63% |
| 2018-09-30 | $2.12 Million | +38.72% |
| 2017-09-30 | $1.53 Million | +2005.47% |
| 2016-09-30 | $72.57K | +534.55% |
| 2015-09-30 | $11.44K | +1067.04% |
| 2014-09-30 | $980.00 | +61.98% |
| 2013-09-30 | $605.00 | -- |